News

Company News & Events

ORYZON to Present Clinical Data on LSD1 Inhibitor ORY-1001 at ASH 2016

14 November 2016

BARCELONA, SPAIN and CAMBRIDGE MA.

• Investor / analyst luncheon event on ORY-1001 to be held Monday, December 5th

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced that the Company will present preliminary safety and efficacy clinical data of its investigational drug ORY-1001, a LSD1 selective inhibitor, at a poster session at the American Society of Hematology (ASH) 58th Annual Meeting and Exposition, being held December 3-6, 2016 in San Diego, California.

Click here to see the full Press Release

Posted In: 
Investors
News

Share this story